ACADIA PHARMACEUTICALS INC Contracts & Agreements

Forms of Standard Performance Stock Unit Grant Notice and Performance Stock Unit Agreement under the Acadia Pharmaceuticals Inc. 2024 Inducement Plan (Filed With SEC on November 7, 2024)

Executive Transition Agreement, dated September 23, 2024, by and between the Company and Stephen R. Davis (Filed With SEC on September 23, 2024)

Employment Agreement, dated September 23, 2024, by and between the Company and Catherine Owen Adams (Filed With SEC on September 23, 2024)

Employment Offer Letter, dated February 22, 2024, between the Registrant and Elizabeth H. Z. Thompson (Filed With SEC on August 7, 2024)

Forms of Nonstatutory Stock Option Grant Notice and Stock Option Agreement under Acadia Pharmaceuticals Inc. 2010 Equity Incentive Plan (Filed With SEC on May 9, 2024)

Forms of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under Acadia Pharmaceuticals Inc. 2010 Equity Incentive Plan (Filed With SEC on May 9, 2024)

Forms of Performance Stock Unit Grant Notice and Performance Stock Unit Award Agreement under Acadia Pharmaceuticals Inc. 2010 Equity Incentive Plan (Filed With SEC on May 9, 2024)

Forms of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement under Acadia Pharmaceuticals Inc. 2010 Equity Incentive Plan (Filed With SEC on February 28, 2024)

Employment Offer Letter, dated January 12, 2024, between the Registrant and Jennifer Rhodes (Filed With SEC on February 28, 2024)

Master Manufacturing Services Agreement and Product Agreement, dated August 3, 2015, by and between the Registrant and Patheon Pharmaceuticals Inc (Filed With SEC on February 28, 2024)

First Amendment to Product Agreement, dated April 25, 2016, by and between the Registrant and Patheon Pharmaceuticals Inc (Filed With SEC on February 28, 2024)

Second Amendment to Product Agreement, dated October 6, 2016, by and between the Registrant and Patheon Pharmaceuticals Inc (Filed With SEC on February 28, 2024)

Third Amendment to Product Agreement, dated December 11, 2017, by and between the Registrant and Patheon Pharmaceuticals Inc (Filed With SEC on February 28, 2024)

Master Commercial Supply Agreement, dated November 16, 2022, by and between the Registrant and Corden Pharma Bergamo S.p.A (Filed With SEC on February 28, 2024)

Commercial Supply Agreement, dated December 15, 2021, by and between the Registrant and F.I.S. Fabbrica Italiana Sintetici S.p.A (Filed With SEC on February 28, 2024)

Product Agreement, effective May 1, 2022, by and between the Registrant and Patheon Pharmaceuticals Inc (Filed With SEC on February 28, 2024)

Commercial Supply Agreement, dated March 1, 2023, by and between the Registrant and CoreRx Inc., as amended by Amendment No. 1, dated August 1, 2023 (Filed With SEC on February 28, 2024)

Master Services Agreement, dated December 15, 2016, by and between Acadia Pharmaceuticals GmbH and Siegfried AG and its affiliates, and Attachment #1, Attachment #2 and Attachment... (Filed With SEC on November 3, 2022)

Change Order #1 to Master Services Agreement Attachment #1, dated January 3, 2017, by and between Acadia Pharmaceuticals GmbH and Siegfried AG (Filed With SEC on November 3, 2022)

Attachment #4, Attachment #5 and Attachment #6, each dated May 12, 2017, to the Master Services Agreement, dated December 15, 2016, by and between Acadia Pharmaceuticals GmbH and... (Filed With SEC on November 3, 2022)

Equity Incentive Plan, as amended (Filed With SEC on August 9, 2022)

Employment Offer Letter, dated June 26, 2018, between the Registrant and Brendan Teehan (Filed With SEC on March 1, 2022)

Employment Offer Letter, dated April 28, 2020, between the Registrant and Mark Schneyer (Filed With SEC on March 1, 2022)

Master Manufacturing Services Agreement and Product Agreement, dated August 3, 2015, by and between the Registrant and Patheon Pharmaceuticals Inc (Filed With SEC on May 6, 2021)

First Amendment to Product Agreement, dated April 25, 2016, by and between the Registrant and Patheon Pharmaceuticals Inc (Filed With SEC on May 6, 2021)

Second Amendment to Product Agreement, dated October 6, 2016, by and between the Registrant and Patheon Pharmaceuticals Inc (Filed With SEC on May 6, 2021)

Third Amendment to Product Agreement, dated December 11, 2017, by and between the Registrant and Patheon Pharmaceuticals Inc (Filed With SEC on May 6, 2021)

Employment Offer Letter, dated April 2, 2018, between the Registrant and Elena Ridloff (Filed With SEC on February 25, 2021)

Attachment #7, dated September 30, 2020, to the Master Services Agreement, dated December 15, 2016, by and between Acadia Pharmaceuticals GmbH and Siegfried AG and its affiliates (Filed With SEC on November 4, 2020)

First Amendment to Office Lease, dated December 23, 2019, between the Registrant and Kilroy Realty, L.P (Filed With SEC on May 8, 2020)

Second Amendment to Office Lease, dated March 12, 2020, between the Registrant and Kilroy Realty, L.P (Filed With SEC on May 8, 2020)

Description of the Registrants Common Stock (Filed With SEC on February 27, 2020)

Underwriting Agreement, dated September 17, 2019 (Filed With SEC on September 18, 2019)

Form of Amended and Restated Warrant to Purchase Common Stock (superseding the form of warrant issued to certain purchasers in a private placement on December 17, 2012) (Filed With SEC on February 27, 2019)

Underwriting Agreement, dated November 27, 2018 (Filed With SEC on November 28, 2018)

Employment Offer Letter, dated July 2, 2018, between the Registrant and Austin D. Kim (Filed With SEC on November 6, 2018)

Lease Agreement between Registrant and Boston Properties Limited partnership, dated May 15, 2018 (Filed With SEC on August 8, 2018)

Update to Description of Executive Officer Annual Incentive Cash Compensation Program (Filed With SEC on May 4, 2018)

Third Amendment to Product Agreement, dated December 11, 2017, by and between the Registrant and Patheon Pharmaceuticals Inc (Filed With SEC on February 27, 2018)

Commercial Supply Agreement, dated February 22, 2018, by and between the Registrant and Catalent Pharma Solutions, LLC (Filed With SEC on February 27, 2018)

ACADIA Pharmaceuticals Inc. Description of Outside Director Compensation Program (Updated July 17, 2017) (Filed With SEC on August 8, 2017)

MSA Attachment No.4 (Filed With SEC on August 8, 2017)

ACADIA Pharmaceuticals Inc. Description of Outside Director Compensation Program (Filed With SEC on May 9, 2017)

ACADIA Pharmaceuticals Inc. 2004 Employee Stock Purchase Plan Offering Adopted by the Board of Directors on February 25, 2004 (Filed With SEC on February 28, 2017)

Master Services Agreement (Filed With SEC on February 28, 2017)

CHANGE ORDER # 1 to MSA Attachment No. 1 [*&***&] (Filed With SEC on February 28, 2017)

Second Amendment to Product Agreement between Patheon Pharmaceuticals Inc. and ACADIA Pharmaceuticals Inc. (Filed With SEC on November 7, 2016)

6,060,606 Shares ACADIA PHARMACEUTICALS INC. UNDERWRITING AGREEMENT (Filed With SEC on August 10, 2016)

ACADIA PHARMACEUTICALS INC. NONSTATUTORY STOCK OPTION GRANT NOTICE (2010 EQUITY INCENTIVE PLAN) (Filed With SEC on February 29, 2016)

EXHIBIT 1 DEFINITION OF GOOD REASON (Filed With SEC on February 29, 2016)

10,344,827 Shares ACADIA PHARMACEUTICALS INC. UNDERWRITING AGREEMENT (Filed With SEC on January 7, 2016)

REGISTRATION RIGHTS AGREEMENT (Filed With SEC on January 7, 2016)

Master Manufacturing Services Agreement August 3, 2015 (Filed With SEC on November 5, 2015)

Co-operation Agreement (Filed With SEC on November 5, 2015)

ACADIA PHARMACEUTICALS INC. EXECUTIVE EMPLOYMENT TRANSITION AGREEMENT (Filed With SEC on May 7, 2015)

ACKNOWLEDGMENT AND ACCEPTANCE (Filed With SEC on May 7, 2015)

SUBLEASE AGREEMENT (Filed With SEC on February 26, 2015)

EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on August 5, 2014)

ACADIA PHARMACEUTICALS INC. CHANGE IN CONTROL SEVERANCE BENEFIT PLAN PARTICIPATION AGREEMENT (Filed With SEC on August 5, 2014)

6,400,000 Shares ACADIA PHARMACEUTICALS INC. UNDERWRITING AGREEMENT (Filed With SEC on March 5, 2014)

EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on February 27, 2014)

ACADIA PHARMACEUTICALS INC. CHANGE IN CONTROL SEVERANCE BENEFIT PLAN (Filed With SEC on February 27, 2014)

FIRST AMENDMENT TO LEASE (Filed With SEC on November 6, 2013)

SIXTH AMENDMENT TO LEASE (Filed With SEC on August 6, 2013)

8,000,000 Shares ACADIA PHARMACEUTICALS INC. UNDERWRITING AGREEMENT (Filed With SEC on May 15, 2013)

ACADIA Pharmaceuticals Inc. Description of Outside DirectorCompensation Program (Filed With SEC on March 12, 2013)

ACADIA Pharmaceuticals Inc. Description of Executive Officer AnnualIncentive Cash Compensation Program (Filed With SEC on March 12, 2013)

ACADIA PHARMACEUTICALS INC. CHANGE IN CONTROL SEVERANCE BENEFIT PLAN (Filed With SEC on March 12, 2013)

FIFTH AMENDMENT TO LEASE (Filed With SEC on November 5, 2012)

SEVENTH AMENDMENT TO COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENTS (Filed With SEC on March 6, 2012)

SIXTH AMENDMENT TO COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENTS (Filed With SEC on May 10, 2011)

Termination Agreement (Filed With SEC on May 10, 2011)

ACADIA PHARMACEUTICALS INC. STOCK OPTION GRANT NOTICE (2010 EQUITY INCENTIVE PLAN) (Filed With SEC on March 10, 2011)

EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on March 10, 2011)

TERMINATION AGREEMENT (Filed With SEC on March 10, 2011)

ACADIA PHARMACEUTICALS INC. 2010 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS:MARCH 12, 2010 APPROVED BY THESTOCKHOLDERS: JUNE 11, 2010 TERMINATION DATE:MARCH 11, 2020 (Filed With SEC on August 9, 2010)

FIFTH AMENDMENT TO COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENTS (Filed With SEC on May 10, 2010)

VOLUME SUBMITTER DEFINED CONTRIBUTION PLAN FIDELITYBASIC PLAN DOCUMENT NO. 14 Acadia Pharmaceuticals 401(k) Plan and Trust (Filed With SEC on March 9, 2010)

VOLUME SUBMITTER DEFINED CONTRIBUTION PLAN (PROFIT SHARING/401(K) PLAN) (Filed With SEC on March 9, 2010)

AMENDMENT TO (Filed With SEC on March 9, 2010)

FOURTH AMENDMENT TO LEASE RE TERMINATIONOF LEASE AS TO 3931 SORRENTO (Filed With SEC on March 9, 2010)

WHEREAS (Filed With SEC on August 5, 2009)

FOURTH AMENDMENT TO COLLABORATIVE RESEARCH, DEVELOPMENT (Filed With SEC on August 5, 2009)

COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on May 11, 2009)

WARRANT (Filed With SEC on August 7, 2008)

COMMON STOCK PURCHASE AGREEMENT (Filed With SEC on August 7, 2008)

REGISTRATION RIGHTS AGREEMENT (Filed With SEC on August 7, 2008)

THIRD AMENDMENT TO COLLABORATIVE RESEARCH, DEVELOPMENT (Filed With SEC on May 5, 2008)

THIRD AMENDMENT TO LEASE (Filed With SEC on March 5, 2008)

ACADIA Pharmaceuticals Inc. Description of Outside Director Compensation Program (Filed With SEC on November 5, 2007)

ACADIA Pharmaceuticals Inc. 5,750,000 Shares (Filed With SEC on April 5, 2007)

ACADIA Pharmaceuticals Inc. Description of Executive Officer Annual Incentive Cash CompensationProgram (Filed With SEC on March 9, 2007)

ACADIA Pharmaceuticals Inc. 4,947,229 Shares (Filed With SEC on April 28, 2006)

SECOND AMENDMENT TO COLLABORATIVE RESEARCH, DEVELOPMENT (Filed With SEC on March 15, 2006)

ACADIA Pharmaceuticals Inc. Description of Executive Officer Annual Incentive Cash CompensationProgram (Filed With SEC on March 15, 2006)

AMENDMENT NO. 2 (Filed With SEC on November 14, 2005)

LEASE AGREEMENT (Filed With SEC on November 14, 2005)

EXHIBIT B (Filed With SEC on May 10, 2005)

ACADIA Pharmaceuticals Inc. Description of Outside Director Compensation Program (Filed With SEC on March 18, 2005)

ACADIA Pharmaceuticals Inc. Description of Executive Officer Annual Incentive Cash Compensation Program (Filed With SEC on March 18, 2005)

COLLABORATIVERESEARCH, DEVELOPMENT AND LICENSE AGREEMENT By and Among (Filed With SEC on May 25, 2004)

COLLABORATIVE RESEARCH, DEVELOPMENT ANDLICENSE AGREEMENT by andamong ACADIA PHARMACEUTICALSINC., VISIONPHARMACEUTICALS L.P. and ALLERGAN, INC. (Filed With SEC on May 25, 2004)

COLLABORATIVERESEARCH, DEVELOPMENT AND LICENSE AGREEMENT Among (Filed With SEC on May 25, 2004)

COLLABORATIVERESEARCH, DEVELOPMENT AND LICENSE AGREEMENT By and Among (Filed With SEC on May 25, 2004)

DEVELOPMENTAGREEMENT (Filed With SEC on May 25, 2004)

ACADIA Pharmaceuticals Inc. (Filed With SEC on May 19, 2004)

ACADIA PHARMACEUTICALS INC. 2004 EQUITYINCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS ON FEBRUARY 25, 2004 AMENDED BY THE BOARD OF DIRECTORS ON MARCH 12, 2004 (Filed With SEC on May 19, 2004)

ACADIA PHARMACEUTICALS INC. (Filed With SEC on May 19, 2004)

GENERAL AGREEMENT (Filed With SEC on May 19, 2004)

CONVERTIBLEPROMISSORY NOTE (Filed With SEC on May 5, 2004)

DEVELOPMENTAGREEMENT (Filed With SEC on May 5, 2004)

AMENDED AND RESTATED STOCKHOLDERS AGREEMENT (Filed With SEC on February 27, 2004)

ACADIA PHARMACEUTICALS INC. WARRANT TO PURCHASE PREFERRED STOCK (Filed With SEC on February 27, 2004)

INDEMNITY AGREEMENT (Filed With SEC on February 27, 2004)

Amended bythe Board of Directors and Stockholders: April 22, 1999 Amended by the Board of Directors: November 3, 2000 Approved by Stockholders:December 22, 2000 Amended by the... (Filed With SEC on February 27, 2004)

FOR RETIREMENTSM100 FIDELITYBASIC PLAN DOCUMENT No. 10 (Filed With SEC on February 27, 2004)

MANAGINGDIRECTOR CONTRACT (Filed With SEC on February 27, 2004)

AMENDMENT TO COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (Filed With SEC on February 27, 2004)

COLLABORATIVE RESEARCH, DEVELOPMENT ANDLICENSE AGREEMENT By and Among (Filed With SEC on February 27, 2004)

Category

Industry

Companies

Contracts

ACADIA PHARMACEUTICALS INC Contracts & Agreements